AndroGel Black / African Ancestry Safety Profile Differences

Why Ancestry Matters for Testosterone Therapy

Black and African ancestry men are not simply a demographic subgroup for marketing purposes. Differences in baseline hormone physiology, co-morbidity burden, renal function, and drug-metabolizing enzyme variants create a distinct clinical risk profile when prescribing AndroGel. The Endocrine Society's 2018 clinical practice guideline on male hypogonadism acknowledges that cardiovascular and renal co-morbidities must be weighted before initiating testosterone therapy, though it stops short of ancestry-specific dosing algorithms.

Population-level data confirm that hypertension affects roughly 57% of non-Hispanic Black adults compared with 43% of non-Hispanic white adults, according to CDC surveillance data. Testosterone therapy raises hematocrit and may modestly increase blood pressure, so starting from a higher baseline cardiovascular burden changes the benefit-risk calculation in a clinically meaningful way.

The Testosterone Trials and Representation Gaps

The Testosterone Trials (T-Trials), a coordinated set of seven placebo-controlled studies in 788 men aged 65 years and older, provided the most rigorous contemporary dataset on testosterone gel efficacy and short-term safety [Snyder et al., NEJM 2016, pubmed.ncbi.nlm.nih.gov/26886521]. Black men represented roughly 4% of that cohort, a figure too small for ancestry-stratified subgroup analyses to reach statistical significance. The cardiovascular findings, including a numerically higher rate of coronary artery calcium progression in the testosterone arm, were therefore reported for the aggregate population rather than by race.

That representational gap means clinicians must triangulate from pharmacogenomic studies, registry data, and physiology rather than from clean head-to-head subgroup trial data. That is the honest starting point.

What "Standard Dosing" Assumes

AndroGel 1.62% is initiated at 40.5 mg/day, titrated to 20.25 mg or 81 mg based on serum total testosterone drawn 2-8 hours after application on day 14 or day 28. The titration target is 400-700 ng/dL total testosterone. That window was established largely in trials with predominantly white enrollees. If free testosterone, not total, is the biologically active fraction, and if SHBG differs by ancestry, then total-testosterone titration targets may systematically over- or under-dose specific populations.

Sex Hormone-Binding Globulin Differences

SHBG is the protein that binds testosterone in circulation, making it biologically inactive. Only the unbound (free) fraction and the albumin-bound fraction act on androgen receptors. Several cross-sectional studies, including analyses from the Third National Health and Nutrition Examination Survey (NHANES III), have found that African American men carry statistically lower SHBG concentrations than non-Hispanic white men, on the order of 3-5 nmol/L lower after adjusting for age, BMI, and fasting insulin [Winters et al., J Clin Endocrinol Metab, pubmed.ncbi.nlm.nih.gov/11502772].

Clinical Implications of Lower SHBG

Lower SHBG means a larger free-testosterone fraction for any given total-testosterone reading. A total testosterone of 550 ng/dL in a man with low SHBG may correspond to a free testosterone that would map to 650-700 ng/dL total in a man with average SHBG. Clinicians relying solely on total testosterone to titrate AndroGel could therefore dose higher than necessary in African ancestry men with low SHBG, pushing free testosterone into ranges associated with polycythemia and increased cardiovascular strain.

Calculating free testosterone with the Vermeulen equation, or measuring it directly by equilibrium dialysis, is a reasonable step before titrating upward in any patient where SHBG is suspected to be low. The American Urological Association's 2018 testosterone deficiency guidelines note that free testosterone measurement is appropriate when SHBG abnormalities are suspected [auajournals.org]. Clinicians should confirm SHBG at baseline for African ancestry patients and factor it into every titration decision.

Prostate-Specific Antigen and SHBG

Lower SHBG also means higher free testosterone delivery to prostate tissue. Black men already carry a 1.7-fold higher prostate cancer incidence compared with white men, according to SEER data cited by the NCI. Adding exogenous testosterone in the context of already-elevated androgen receptor sensitivity (a physiologic pattern documented in Black men in several studies) warrants more frequent PSA monitoring, not the same 12-month interval considered adequate in lower-risk populations.

Pharmacogenomics: CYP19A1, UGT2B17, and SRD5A2

Three genes are most clinically relevant for testosterone pharmacogenomics in the context of AndroGel use.

CYP19A1 (Aromatase)

Testosterone is converted to estradiol by aromatase, encoded by CYP19A1. At least 18 single-nucleotide variants in CYP19A1 show population-frequency differences across ancestries, catalogued in the PharmGKB database. Higher aromatase activity shifts testosterone toward estradiol, reducing androgenic effect while increasing gynecomastia risk and potentially lowering the hematocrit response. African ancestry populations carry CYP19A1 haplotypes at distinct frequencies compared with European ancestry populations, though the direction of net effect on aromatase activity is not uniform across all variants. Measuring estradiol at baseline and after dose titration gives actionable data on where each patient sits on the aromatization spectrum.

UGT2B17 (Glucuronidation and Clearance)

UGT2B17 encodes the enzyme that glucuronidates testosterone and its metabolites for renal excretion. A common copy-number variant, UGT2B17*2 (deletion), dramatically reduces testosterone glucuronidation and is present in roughly 10% of African Americans, compared with 67% of some East Asian populations and intermediate frequencies in European ancestry groups [Xue et al., Pharmacogenomics, pubmed.ncbi.nlm.nih.gov/17935512]. Men with reduced UGT2B17 activity may accumulate testosterone or dihydrotestosterone at higher steady-state concentrations even on standard doses of AndroGel, increasing polycythemia and prostate risk. UGT2B17 genotyping is not yet standard clinical practice, but its effect on testosterone pharmacokinetics is well-established mechanistically.

SRD5A2 (5-Alpha Reductase Type 2)

SRD5A2 converts testosterone to dihydrotestosterone (DHT), which has five times higher androgen receptor affinity than testosterone and drives prostate growth and scalp hair loss. Population genetic studies show that the V89L variant of SRD5A2, associated with higher enzyme activity and higher DHT/testosterone ratios, is more common in men of African ancestry than European ancestry [Ntais et al., Cancer Epidemiol Biomarkers Prev, pubmed.ncbi.nlm.nih.gov/12917199]. Higher DHT generation from the same AndroGel dose may contribute to the excess prostate cancer risk and means that clinicians should monitor DHT if patients report rapid prostate symptom progression on therapy.

Cardiovascular and Hypertension Risk

Testosterone therapy raises red blood cell mass, increasing blood viscosity and potentially systolic blood pressure. In Black patients who begin therapy with a hypertension prevalence approaching 57%, any additional pressor effect of testosterone is additive to existing vascular risk.

Renin-Angiotensin System Interactions

Black patients have, on average, lower plasma renin activity than white patients, a physiologic pattern that underpins the well-documented blunted response to ACE inhibitors and ARBs as monotherapy [Douglas et al., Hypertension, pubmed.ncbi.nlm.nih.gov/12531924]. Testosterone stimulates the renin-angiotensin-aldosterone system through androgen receptor-mediated upregulation of angiotensinogen synthesis in the liver. In a patient already on an ACE inhibitor or ARB for blood pressure control, adding testosterone gel may partially counteract the antihypertensive mechanism. Calcium channel blockers or thiazide diuretics, which are more effective as monotherapy in low-renin hypertension, may be preferable antihypertensives in this setting, and blood pressure should be rechecked within four weeks of initiating or up-titrating AndroGel.

Hematocrit and Polycythemia

The Endocrine Society 2018 guideline recommends checking hematocrit at 3-6 months and annually thereafter, withholding therapy if hematocrit exceeds 54% [academic.oup.com/jcem]. African ancestry men do not inherently have higher baseline hematocrit, but the combination of exogenous testosterone, possible sickle cell trait (present in approximately 8% of Black Americans), and pre-existing CKD-related anemia creates a more complex hematologic picture. Sickle cell trait in and of itself is not a contraindication to testosterone therapy, but polycythemia in a patient with sickle trait raises viscosity in a way that could theoretically increase vaso-occlusive risk. This warrants a documented discussion in the clinical note.

Chronic Kidney Disease Risk

Black Americans develop end-stage renal disease at 3.4 times the rate of white Americans, driven partly by APOL1 high-risk variants (G1 and G2 alleles) present in approximately 13% of African Americans [pubmed.ncbi.nlm.nih.gov/20647424]. Testosterone therapy is generally not contraindicated in CKD, but renal impairment affects the pharmacokinetics of testosterone metabolites and alters SHBG in complex ways. CKD decreases SHBG (increasing free testosterone) while simultaneously impairing hepatic androgen metabolism. The net effect is unpredictable without direct free-testosterone measurement.

APOL1 and Clinical Decision-Making

APOL1 genotyping is not yet routine outside of transplant medicine, but clinicians treating Black men with AndroGel should assess renal function with eGFR and urine albumin-to-creatinine ratio at baseline and every 12 months. An eGFR below 30 mL/min/1.73 m² should prompt nephrology co-management before initiating testosterone therapy, given the fluid retention and erythrocytosis risk.

Sodium Retention

AndroGel, like all testosterone formulations, carries an FDA-labeled warning for sodium and water retention, which may exacerbate hypertension and heart failure. In a patient with CKD stage 3 or higher, even modest sodium retention from testosterone therapy can push blood pressure up by 5-10 mmHg. Baseline and follow-up assessments should include weight, blood pressure, and lower-extremity edema evaluation at every visit.

G6PD Deficiency

Glucose-6-phosphate dehydrogenase (G6PD) deficiency affects approximately 10-15% of Black American males, compared with approximately 1-2% of white males, due to the high prevalence of the A- variant in populations with historical malaria exposure [pubmed.ncbi.nlm.nih.gov/11172061]. Testosterone itself is not a known direct trigger of G6PD-related hemolysis. The clinical relevance arises from co-prescribing.

Drug Interaction Considerations

Men on AndroGel who also take medications commonly prescribed alongside testosterone therapy (including certain antibiotics, antimalarials, or anti-inflammatory agents) may be at risk for hemolytic episodes if G6PD deficient. Dapsone, nitrofurantoin, and rasburicase are well-established hemolysis triggers in G6PD-deficient individuals. Before adding any new medication to a regimen that includes AndroGel, the prescriber should check the G6PD status of the patient and cross-reference the new agent against the G6PD deficiency drug list maintained by the WHO.

Baseline G6PD Screening

The American Academy of Family Physicians does not currently list G6PD screening as a universal recommendation, but the CDC notes that screening is clinically warranted before certain drug exposures, particularly in high-prevalence populations. A one-time G6PD qualitative assay (less than $20 in most lab panels) at the time of AndroGel initiation provides durable information that protects the patient across the entire duration of therapy.

Dermal Absorption and Application-Site Differences

AndroGel is applied to the shoulders, upper arms, or abdomen. Absorption is estimated at approximately 10% of applied dose and varies with skin thickness, hydration, and regional blood flow. Melanin content does not directly alter testosterone absorption through the stratum corneum, but skin condition and hydration do. Patients with eczema, keloidal scarring, or other dermatologic differences common in African ancestry populations should apply the gel to unaffected skin to maintain consistent absorption.

The FDA label for AndroGel 1.62% reports a coefficient of variation in steady-state testosterone AUC of approximately 35%, meaning absorption variability is high even in controlled trial conditions [accessdata.fda.gov]. That variability underscores the need for serum level monitoring rather than fixed-dose assumptions.

Monitoring Protocol for Black and African Ancestry Patients on AndroGel

Standard Endocrine Society monitoring applies to all patients: serum testosterone at 3-6 months, hematocrit at 3-6 months, PSA at 3-12 months, and digital rectal exam annually in men over 40. For Black and African ancestry patients, the HealthRX medical team recommends the following additions based on the physiologic and pharmacogenomic considerations above.

Recommended Additions to Standard Monitoring

First, measure SHBG at baseline and calculate free testosterone using the Vermeulen equation. If free testosterone is already at or above the upper quartile of the normal range, titrating total testosterone to 700 ng/dL is likely excessive. Second, obtain a baseline eGFR and spot urine albumin-to-creatinine ratio. Third, check G6PD status with a qualitative assay before initiating therapy. Fourth, measure serum estradiol (LC-MS/MS method, not immunoassay) at the first follow-up visit at 4 weeks, as it provides a functional readout of CYP19A1 aromatase activity. Fifth, recheck blood pressure within four weeks of any dose change, given the higher baseline hypertension prevalence and the renin-angiotensin interactions described above.

As the Endocrine Society's 2018 guideline states directly: "We suggest that clinicians consider individual patient characteristics, including comorbid conditions, to determine the frequency and intensity of monitoring" [academic.oup.com/jcem].

PSA Monitoring Frequency

Given the 1.7-fold higher prostate cancer incidence in Black men (SEER), PSA should be checked at 3 months rather than 12 months after AndroGel initiation in this population. A PSA rise of more than 1.4 ng/mL above baseline within any 12-month window or a single PSA exceeding 4.0 ng/mL warrants urology referral before continuing therapy.

Dosing Considerations

AndroGel should not be dosed differently by race in a blanket algorithmic way. The correct adjustment is physiologic: measure free testosterone (or calculate it from SHBG), measure estradiol, check renal function, and titrate to the free-testosterone target rather than the total-testosterone target alone. For most men, free testosterone of 9-30 pg/mL (by equilibrium dialysis) or a calculated value of 70-250 pg/mL using Vermeulen represents normal physiology.

If SHBG is confirmed low (below 20 nmol/L, which is more common in African ancestry men with obesity, insulin resistance, or liver disease), the starting dose of AndroGel 1.62% at 40.5 mg/day may achieve higher-than-expected free testosterone. In those patients, the titration visit at day 14 may reveal a total testosterone already at 600-700 ng/dL with free testosterone at the top of the reference range. Holding dose rather than titrating upward is the appropriate response.